Spots Global Cancer Trial Database for hematological malignancies
Every month we try and update this database with for hematological malignancies cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Pharmacokinetics and Safety Study of Siremadlin (HDM201) in Participants With Mild, Moderate and Severe Hepatic Impairment | NCT05599932 | Hepatic Impairm... | Siremadlin | 18 Years - 75 Years | Novartis | |
| Umbilical Cord Blood Stem Cell Transplantation in Adults With Advanced Blood Disorders or Cancer | NCT00312429 | Hematologic Neo... | Stem Cell Trans... | 18 Years - 70 Years | Duke University | |
| Naive T-Cell Depleted DLI Following Allo Stem Cell Transplant | NCT01627275 | Hematological M... | Naive T Cell De... | 18 Years - | Duke University | |
| A Two-part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of KRP203 in Patients Undergoing Stem Cell Transplant for Hematological Malignancies | NCT01830010 | Hematological M... | Study Part 1: K... Study Part 2: K... Study Part 2: K... | 18 Years - 65 Years | Novartis | |
| Descriptive Study of the Efficacy of Treatments for Blastic Dendritic Cell Neoplasm (BPDCN) | NCT02859623 | Blastic Plasmac... Hematological M... | - | Centre Hospitalier Universitaire de Besancon | ||
| Trial to Evaluate Palifermin in the Reduction of Acute Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Allogeneic Marrow/Peripheral Blood Progenitor Cell (PBPC) Transplantation | NCT00189488 | Graft Versus Ho... Hematologic Mal... | Palifermin Placebo Conditioning Re... Allogeneic stem... Methotrexate | 18 Years - | Swedish Orphan Biovitrum | |
| A Study of GNC-035 in Relapsed or Refractory Non-Hodgkin 's Lymphoma and Other Hematological Malignancies | NCT06066203 | Non-hodgkin's L... | GNC-035 | 18 Years - 75 Years | Sichuan Baili Pharmaceutical Co., Ltd. | |
| Epidemiology of Diarrheal Diseases in Pediatric Oncology Patients | NCT02464098 | Diarrhea | - 18 Years | St. Jude Children's Research Hospital | ||
| Haploidentical Hematopoietic Stem Cell Transplantation Using A Novel Clofarabine Containing Conditioning Regimen For Patients With Refractory Hematologic Malignancies | NCT00824135 | Hematologic Mal... | Clofarabine Stem Cell Trans... OKT3 Thiotepa Melphalan Mycophenolate m... Rituximab G-CSF | - 21 Years | St. Jude Children's Research Hospital | |
| Observational Study Investigating the Response Rate of Itraconazole Injection in Treating Immunocompromised Patients | NCT01060462 | Hematological M... Neutropenia Fever | Pts. w/ neutrop... | 18 Years - | Janssen Korea, Ltd., Korea | |
| Allogeneic Immunotherapy for Hematological Malignancies by Selective Depletion of Regulatory T Cells | NCT03236129 | Hematological M... Regulatory T Ce... Relapse | T-reg depleted ... Standard DLI | - | Assistance Publique - Hôpitaux de Paris | |
| Immunogenicity of Covid-19 Vaccination for Patients With Hematological Malignancies | NCT04878822 | Immunogenicity Hematological M... Covid-19 Vaccine Respons... | 18 Years - | Ospedale di Circolo - Fondazione Macchi | ||
| Tacrolimus and Thymoglobulin, as GvHD Prophylaxis in Patients Undergoing Related Donor HCT | NCT01246206 | Hematological M... | Tacrolimus and ... | 18 Years - 70 Years | Barbara Ann Karmanos Cancer Institute | |
| Naive T-Cell Depleted DLI Following Allo Stem Cell Transplant | NCT01627275 | Hematological M... | Naive T Cell De... | 18 Years - | Duke University | |
| Safety and Anti-Disease Activity of CHR-2797 (Tosedostat) in Elderly and/or Treatment Refractory Patients With Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM) | NCT00689000 | Acute Myeloid L... Myelodysplastic... Multiple Myelom... | CHR-2797 (tosed... | 18 Years - | Chroma Therapeutics | |
| Stem Cell Transplantation for Hematological Malignancies | NCT00176839 | Leukemia, Lymph... AML MDS | Stem Cell Trans... Busulfan Cyclophosphamid... Melphalan G-CSF ATG | - 35 Years | Masonic Cancer Center, University of Minnesota | |
| Sequential Radiotherapy With CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies With Extramedullary Lesions | NCT04790747 | Hematological M... | CAR-T cells | 15 Years - | Zhejiang University | |
| Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Cells, in Patients With HM | NCT01816230 | Hematological M... Acute Lymphobla... Acute Myeloid L... Myelodysplastic... | NiCord® | 12 Years - 65 Years | Gamida Cell ltd | |
| Molecular Testing of Cancer by Integrated Genomic, Transcriptomic, and Proteomic Analysis | NCT02213822 | Solid Tumors Hematological M... | Molecular Analy... | 18 Years - | Rhode Island Hospital | |
| A Russian Prospective Observational Study of Invasive Fungal Infections in Patients With Acute Leukemia and Hematopoietic Stem Cell Transplantation | NCT01519648 | Invasive Fungal... | 1 Year - 95 Years | National Hematological Society, Russia | ||
| Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) for the Treatment of Hematological Malignancies | NCT00438178 | Hematological M... | Obatoclax mesyl... | 18 Years - | Teva Branded Pharmaceutical Products R&D, Inc. | |
| A Study of Nemtabrutinib (MK-1026) in China Participants With Relapsed or Refractory Hematologic Malignancies (MK-1026-005) | NCT05347225 | Hematological M... | Nemtabrutinib | 18 Years - | Merck Sharp & Dohme LLC | |
| Haploidentical Hematopoietic Stem Cell Transplantation Using A Novel Clofarabine Containing Conditioning Regimen For Patients With Refractory Hematologic Malignancies | NCT00824135 | Hematologic Mal... | Clofarabine Stem Cell Trans... OKT3 Thiotepa Melphalan Mycophenolate m... Rituximab G-CSF | - 21 Years | St. Jude Children's Research Hospital | |
| Expanded Access of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies | NCT04260698 | Hematological M... | omidubicel | 12 Years - | Gamida Cell ltd | |
| A Clinical Study of HMPL-506 in Patients With Hematological Malignancies | NCT06387082 | Hematological M... | HMPL-506 | 18 Years - | Hutchmed | |
| Minitransplants With HLA-matched Donors : Comparison Between 2 GVHD Prophylaxis Regimens | NCT01428973 | Graft-Versus-Ho... Hematological M... | Mycophenolate m... Sirolimus | 16 Years - 75 Years | University of Liege | |
| Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies | NCT01221857 | Acute Lymphobla... Acute Myelogeno... Myelodysplastic... Non-Hodgkin's L... Hodgkin's Disea... | NiCord® | 8 Years - 65 Years | Gamida Cell ltd | |
| Nurse-initiated Conversations for Early Integration of Palliative Care in Pediatric Oncology | NCT05306509 | Solid Tumor Hematological M... | NiCE Routine PPC | - 18 Years | Children's Hospital of Fudan University | |
| Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma | NCT03145181 | Hematological M... | Teclistamab (IV... Teclistamab(SC) | 18 Years - | Janssen Research & Development, LLC | |
| Pasireotide in Prevention of GI Toxicity | NCT02215070 | Hematological M... | Pasireotide | 18 Years - | Duke University | |
| In Vitro Drug Sensitivity Testing of Fresh Human Samples | NCT05001386 | Myeloproliferat... Lymphoprolifera... | Blood collectio... | 18 Years - | Hospices Civils de Lyon | |
| Stem Cell Transplantation for Hematological Malignancies | NCT00176839 | Leukemia, Lymph... AML MDS | Stem Cell Trans... Busulfan Cyclophosphamid... Melphalan G-CSF ATG | - 35 Years | Masonic Cancer Center, University of Minnesota | |
| A Study Evaluating the Efficacy and Safety of Aprepitant in Autologous Hematopoietic Stem Cell Transplantation | NCT02576327 | Vomiting | Tropisetron Dexamethasone Aprepitant | 18 Years - 65 Years | Peking University | |
| Concentrated Citrate Locking to Reduce the Incidence of CVC-related Complications in Hematological Patients | NCT01820962 | Hematological M... Bacteremia Thrombosis | heparin concentrated ci... | 18 Years - | Maastricht University Medical Center | |
| Molecular Testing of Cancer by Integrated Genomic, Transcriptomic, and Proteomic Analysis | NCT02213822 | Solid Tumors Hematological M... | Molecular Analy... | 18 Years - | Rhode Island Hospital | |
| Naive T-Cell Depleted DLI Following Allo Stem Cell Transplant | NCT01627275 | Hematological M... | Naive T Cell De... | 18 Years - | Duke University | |
| A Study of TQB3820 in Patients With Hematological Malignancies | NCT05020639 | Hematological M... | TQB3820 tablets | 18 Years - | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| VPA Expanded UCB Transplantation for Treatment of Patients With Hematological Malignancies | NCT03885947 | Hematological M... Acute Leukemia ... Acute Lymphobla... Myelodysplastic... Non-Hodgkin Lym... Hodgkin Lymphom... | Cord blood stem... Valproic Acid Fludarabine cytoxan Thiotepa TBI | 18 Years - 65 Years | Icahn School of Medicine at Mount Sinai | |
| A Study of Nemtabrutinib (MK-1026) in China Participants With Relapsed or Refractory Hematologic Malignancies (MK-1026-005) | NCT05347225 | Hematological M... | Nemtabrutinib | 18 Years - | Merck Sharp & Dohme LLC | |
| Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT) | NCT01379209 | Graft Versus Ho... | RGI-2001 Calcineurin Inh... Allogeneic Hema... Conditioning Re... Allogeneic Bone... Methotrexate Mofetil Mycophe... sirolimus | 18 Years - | Regimmune Corporation | |
| Stem Cell Transplantation for Hematological Malignancies | NCT00176839 | Leukemia, Lymph... AML MDS | Stem Cell Trans... Busulfan Cyclophosphamid... Melphalan G-CSF ATG | - 35 Years | Masonic Cancer Center, University of Minnesota | |
| Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy | NCT00469729 | Hematologic Mal... Acute Myeloid L... Lymphoid Leukem... Chronic Myeloid... Hodgkin's Disea... Non-Hodgkin's L... Myelodysplastic... | StemEx® | 12 Years - 55 Years | Gamida Cell -Teva Joint Venture Ltd. | |
| Cologne Cohort of Neutropenic Patients (CoCoNut) | NCT01821456 | Hematological M... Cancer Chemotherapy Neutropenia Immunosuppressi... | Antiinfectives | 1 Year - | University Hospital of Cologne | |
| Safety, Tolerability and Pharmacokinetics Study of KPG-818 in Hematological Malignancies Subjects | NCT04283097 | Hematological M... | KPG-818 | 18 Years - | Kangpu Biopharmaceuticals, Ltd. | |
| Study of a Reduced-toxicity "Submyeloablative" Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation in Patients With Hematological Malignancies | NCT00841724 | Hematological M... | Fludarabine, Bu... | 18 Years - 65 Years | Nantes University Hospital | |
| Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome | NCT02269592 | Monoclonal Gamm... Chronic Lymphoc... Myelodysplastic... Hematological M... B-cell Malignan... Myelodysplastic... IgG Monoclonal ... Smoldering Mult... Waldenstrom Mac... | 18 Years - | Dana-Farber Cancer Institute | ||
| A Research Study of Bone Marrow Transplantation From Unrelated or Partially Matched Related Donors | NCT01349101 | Hematological M... | Total Body Irra... Cyclophosphamid... Tacrolimus Mycophenolate m... Fludarabine Busulfan Hematopoietic s... | 18 Years - | Thomas Jefferson University | |
| Safety and Efficacy Evaluation of IM19 Cells | NCT03344705 | Hematological M... | IM19 CAR-T Fludarabine Cyclophosphamid... | 4 Years - 75 Years | Beijing Immunochina Medical Science & Technology Co., Ltd. | |
| Study of ABT-751 in Patients With Refractory Hematologic Malignancies | NCT00047489 | Hematological M... | ABT-751 | 17 Years - | M.D. Anderson Cancer Center | |
| Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation | NCT00720629 | Graft Versus Ho... | Visilizumab Tacrolimus Methotrexate Antithymocyte g... Tacrolimus Methotrexate | 18 Years - 60 Years | H. Lee Moffitt Cancer Center and Research Institute | |
| Extracorporal Photopheresis Pilot Study | NCT00930566 | Hematological M... | methoxsalen Extracoporal Ph... | 18 Years - 65 Years | Hospices Civils de Lyon | |
| Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation | NCT00720629 | Graft Versus Ho... | Visilizumab Tacrolimus Methotrexate Antithymocyte g... Tacrolimus Methotrexate | 18 Years - 60 Years | H. Lee Moffitt Cancer Center and Research Institute | |
| The Study of ICP-248 in Patients With Mature B-cell Malignancies | NCT05728658 | Hematological M... | ICP-248 | 18 Years - 80 Years | Beijing InnoCare Pharma Tech Co., Ltd. | |
| MiniMUD Study - Unrelated Reduced Intensity Conditioning With Treosulfan® for Allogeneic Stem Cell Transplantation in Patients With Hematological Malignancies | NCT00129155 | Hematological M... Allogeneic Tran... | treosulfan | 18 Years - 65 Years | Hospices Civils de Lyon | |
| Immunoablative Mini Transplant (Hematopoietic Peripheral Blood Stem Cell Transplant [HPBSC]) | NCT00179764 | Tumors Malignant Melan... Hematological M... Myelogenous Leu... Leukemia, Lymph... | Immunoablative ... Busulfan pharma... Central Nervous... | - 21 Years | Ann & Robert H Lurie Children's Hospital of Chicago | |
| Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies | NCT02576496 | Hematological M... Multiple Myelom... Hodgkin's Lymph... Cutaneous T Cel... | Tinostamustine | 18 Years - | Mundipharma Research Limited | |
| Prognostic Value of "CD200" in Hematological Malignancies. Hematological Malignancies Comprise a Group of Malignant Clonal Disorders Arising From the Hematopoietic Tissues , Including Leukemia , Multiple Myeloma , and They Have a High Morbidity and Mortality | NCT06258629 | Hematological M... | Flowcytometry o... | 1 Year - 60 Years | Sohag University | |
| Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Cells, in Patients With HM | NCT01816230 | Hematological M... Acute Lymphobla... Acute Myeloid L... Myelodysplastic... | NiCord® | 12 Years - 65 Years | Gamida Cell ltd | |
| An Evaluation of the Effect of 'Open Window' on Psychological Well-being and Experience of Stem Cell Transplantation | NCT00348959 | Hematological M... | 'Open Window' P... | 16 Years - | St. James's Hospital, Ireland | |
| Emotion And Symptom-focused Engagement (EASE): An Intervention for Individuals With Acute Leukemia | NCT02353559 | Acute Leukemia | EASE | 18 Years - | University Health Network, Toronto | |
| Etoposide+Cytarabine+PEG-rhG-CSF as First Line Mobilization Regimen of Hematopoietic Stem Cells in Patients With Hematological Malignancies | NCT05536154 | Lymphoma Multiple Myelom... | Etoposide Cytarabine PEG-rhG-CSF | 18 Years - 75 Years | The Affiliated People's Hospital of Ningbo University | |
| Antibacterial Prophylaxis vs no Prophylaxis for Hematological Malignancies Patients Before Allo-HSCT | NCT03733340 | Antibacterial P... Hematological M... Allogenetic Hem... Imipenem | Imipenem | 14 Years - | Nanfang Hospital, Southern Medical University | |
| Safety and Tolerability of RGB-286638 in Patients With Selected, Relapsed or Refractory Hematological Malignancies | NCT01168882 | Hematological M... | RGB-286638 | 18 Years - | Agennix | |
| Allogeneic HCT With HLA-matched Donors : a Phase II Randomized Study Comparing 2 Nonmyeloablative Conditionings | NCT00603954 | Hematological M... | Conditioning re... Conditioning re... | - 75 Years | University of Liege | |
| Tissue Microarray of Hematological Malignancies | NCT04142372 | Hematological M... | - | Tampere University Hospital | ||
| WB-EMS and Nutrition in Patients With Hematological Malignancies | NCT03556748 | Hematologic Dis... Cachexia; Cance... Leukemia Myeloma Lymphoma Cancer | whole-body elec... | 18 Years - | University of Erlangen-Nürnberg Medical School | |
| Autologous Cytomegalovirus (CMV)-Specific Cytotoxic T Cells for Cytomegalovirus (CMV) Reactivation | NCT02210065 | Leukemia Lymphoma | Cytomegalovirus... | 18 Years - | M.D. Anderson Cancer Center | |
| Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning | NCT03852407 | Acute Myeloid L... Myelodysplastic... Chronic Myeloid... Myeloproliferat... Myeloproliferat... Acute Lymphoid ... Multiple Myelom... Chronic Lymphoi... Non Hodgkin Lym... Hodgkin Lymphom... | Thymoglobulin Melphalan Fludarabine Cyclophosphamid | 18 Years - 75 Years | University of Liege | |
| Prevention of Acute Graft Versus Host Disease in Patients Undergoing Allogeneic ApoGraft Stem Cell Transplantation | NCT02828878 | Hematological M... | Allogeneic MPBC... | 18 Years - 70 Years | Cellect Biotechnology | |
| Combination of ATG-based Conditioning Regimen and PTCy for GVHD Prevention in Allo-HSCT After PD-1 Blockade | NCT06238245 | Graft-versus-ho... Hematological M... | Cyclophosphamid | 18 Years - | Beijing 302 Hospital | |
| The Study of ICP-248 in Patients With Mature B-cell Malignancies | NCT05728658 | Hematological M... | ICP-248 | 18 Years - 80 Years | Beijing InnoCare Pharma Tech Co., Ltd. | |
| Impact of DMSO Concentrations on Hematopoietic Recovery After Autologous HSC Transplantation. | NCT02452099 | Multiple Myelom... Lymphomas Leukemias | Cryopreservatio... Cryopreservatio... Cryopreservatio... | 18 Years - | Maria Sklodowska-Curie National Research Institute of Oncology | |
| Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Cells, in Patients With HM | NCT01816230 | Hematological M... Acute Lymphobla... Acute Myeloid L... Myelodysplastic... | NiCord® | 12 Years - 65 Years | Gamida Cell ltd | |
| PRevention Of BLeeding in hEmatological Malignancies With Antifibrinolytic (Epsilon Aminocaproic Acid) | NCT02074436 | Hematological M... Thrombocytopeni... | EACA Platelet transf... | 19 Years - | Emory University | |
| Safety and Anti-Disease Activity of Oral Tosedostat (CHR-2797) in Elderly Subjects With Refractory or Relapsed AML | NCT00780598 | Acute Myeloid L... AML | Tosedostat | 60 Years - | Chroma Therapeutics | |
| Safety and Efficacy Evaluation of IM19 Cells | NCT03344705 | Hematological M... | IM19 CAR-T Fludarabine Cyclophosphamid... | 4 Years - 75 Years | Beijing Immunochina Medical Science & Technology Co., Ltd. | |
| Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological Cancer | NCT01607892 | Hematological M... | KPT-330 | 18 Years - | Karyopharm Therapeutics Inc | |
| Allogeneic Immunotherapy of Hematological Malignancies Using Regulatory T-cell Selective Depletion | NCT06180499 | Hematological M... Regulatory T Ce... Relapse | T-reg depleted ... | 18 Years - | Assistance Publique - Hôpitaux de Paris | |
| Impact of Child Positioning on Pain During a Lumbar Puncture | NCT02834156 | Hematological M... | LP in a seated ... LP in a lying p... | 2 Years - 18 Years | Centre Hospitalier Universitaire de Nice | |
| A Research Study of Bone Marrow Transplantation From Unrelated or Partially Matched Related Donors | NCT01349101 | Hematological M... | Total Body Irra... Cyclophosphamid... Tacrolimus Mycophenolate m... Fludarabine Busulfan Hematopoietic s... | 18 Years - | Thomas Jefferson University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
